Objectives:

Most ovarian cancers are of epithelial origin. The purpose of this study was to evaluate clinical characteristics, clinical approach and survival of the rare clear cell type epithelial ovarian cancers, which are a special subgroup of epithelial ovarian cancers

Materials and Methods:

The records of the patients who were followed up with a histopathological diagnosis of clear cell type epithelial ovarian cancer between 01.01.2010 and 31.12.2020 in the Department of Medical Oncology at Ankara University Faculty of Medicine were reviewed retrospectively. The patients’ ages, stages at the time of diagnosis, histopathological diagnosis after surgery, chemotherapy regimens, overall survival (OS) and progression-free survival (PFS) were assessed.

Results:

The median age of 11 patients included in the study was 53 (22-70) years. While 4 of the patients were diagnosed at stage I according to surgical staging, the other 7 patients were found to be stage 3c. At the time of diagnosis, the median CA125 level of the patients was 86 IU/mL (10-3122), while 3 patients had normal CA125 levels. Three patients had concomitant endometriosis. While only one patient received neoadjuvant chemotherapy, all patients underwent debulking surgery. All patients received adjuvant chemotherapy after surgery. When the progression-free survival and overall survival of the patients at the end of the follow-up period were examined, the median progression-free survival (mPFS) was 9 months for 7 patients who relapsed with distant metastases after adjuvant therapy. The median overall survival (mOS) was 37 months.

Conclusion:

Although early-stage clear cell epithelial ovarian cancers have similar survival to other early-stage epithelial cancers, worse survival is observed in advanced stages.

Keywords: Ovarian Cancer, Cell Clear, Chemotherapy